Latest filing published 17 Jul 2026 for Vaxart, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of James B. Breitmeyer across 3 companies, led by Oncternal Therapeutics, Inc., Vaxart, Inc. and Zogenix, Inc. Between 3 January 2022 and 16 July 2026, the trades on record add up to 10 filings.
On the market, this insider has only ever bought: 2 purchases, €64k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 7 share grants.
Most recently, on 17 July 2026, the filings show a share grant in Vaxart, Inc. The last insider purchase was made public on 17 April 2023, 1,280 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations